• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

RANK配体抑制后骨巨细胞瘤的组织学消退

Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition.

作者信息

Dietrich Martin F, Cavuoti Dominick, Landay Michael, Arriaga Yull E

机构信息

University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

J Investig Med High Impact Case Rep. 2014 Nov 23;2(4):2324709614560216. doi: 10.1177/2324709614560216. eCollection 2014 Oct-Dec.

DOI:10.1177/2324709614560216
PMID:26425630
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4528877/
Abstract

Lung metastases are a rare complication of giant cell tumors of bone. We herein describe an interesting case of histological regression and size reduction of lung metastases originating from a primary giant cell tumor of bone in response to the RANK ligand inhibitor denosumab.

摘要

肺转移是骨巨细胞瘤罕见的并发症。我们在此描述了一例有趣的病例,源于骨原发性巨细胞瘤的肺转移灶在接受RANK配体抑制剂地诺单抗治疗后出现组织学消退和体积缩小。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2221/4528877/a21f4a10c305/10.1177_2324709614560216-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2221/4528877/643061167ee3/10.1177_2324709614560216-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2221/4528877/a21f4a10c305/10.1177_2324709614560216-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2221/4528877/643061167ee3/10.1177_2324709614560216-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2221/4528877/a21f4a10c305/10.1177_2324709614560216-fig2.jpg

相似文献

1
Histological Regression of Giant Cell Tumor of Bone Following RANK Ligand Inhibition.RANK配体抑制后骨巨细胞瘤的组织学消退
J Investig Med High Impact Case Rep. 2014 Nov 23;2(4):2324709614560216. doi: 10.1177/2324709614560216. eCollection 2014 Oct-Dec.
2
Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.地舒单抗可诱导骨巨细胞瘤患者肿瘤缩小和骨形成。
Clin Cancer Res. 2012 Aug 15;18(16):4415-24. doi: 10.1158/1078-0432.CCR-12-0578. Epub 2012 Jun 18.
3
Denosumab for the treatment of giant cell tumor of the bone.地诺单抗用于治疗骨巨细胞瘤。
Future Oncol. 2015;11(13):1881-94. doi: 10.2217/fon.15.94.
4
Denosumab: benefits of RANK ligand inhibition in cancer patients.地舒单抗:核因子-κB 受体活化因子配体抑制剂在癌症患者中的获益。
Curr Opin Support Palliat Care. 2011 Sep;5(3):258-64. doi: 10.1097/SPC.0b013e328349731c.
5
Denosumab-treated Giant Cell Tumor of Bone Exhibits Morphologic Overlap With Malignant Giant Cell Tumor of Bone.地诺单抗治疗的骨巨细胞瘤与骨恶性巨细胞瘤存在形态学重叠。
Am J Surg Pathol. 2016 Jan;40(1):72-80. doi: 10.1097/PAS.0000000000000506.
6
Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.地诺单抗在肺癌患者中的治疗潜力:超越预防骨骼并发症
Clin Lung Cancer. 2015 Nov;16(6):431-46. doi: 10.1016/j.cllc.2015.06.004. Epub 2015 Jun 25.
7
Effect of denosumab on recurrent giant cell reparative granuloma of the lumbar spine.地诺单抗对腰椎复发性巨细胞修复性肉芽肿的影响。
Spine (Phila Pa 1976). 2015 May 15;40(10):E601-8. doi: 10.1097/BRS.0000000000000862.
8
Response of Aneurysmal Bone Cyst to Denosumab.动脉瘤样骨囊肿对地诺单抗的反应。
Spine (Phila Pa 1976). 2015 Nov;40(22):E1201-4. doi: 10.1097/BRS.0000000000001027.
9
Giant cell tumors of the spine: has denosumab changed the treatment paradigm?脊柱巨细胞瘤:地诺单抗是否改变了治疗模式?
J Neurosurg Spine. 2015 May;22(5):526-33. doi: 10.3171/2014.10.SPINE13937. Epub 2015 Feb 20.
10
Critical hypercalcemia following discontinuation of denosumab therapy for metastatic giant cell tumor of bone.停用地诺单抗治疗转移性骨巨细胞瘤后出现的严重高钙血症。
Pediatr Blood Cancer. 2015 Jun;62(6):1078-80. doi: 10.1002/pbc.25393. Epub 2015 Jan 3.

引用本文的文献

1
Giant-cell-poor giant cell tumor of bone: report of two cases and literature review.骨巨细胞瘤:报告两例病例并文献复习。
Skeletal Radiol. 2023 Sep;52(9):1791-1798. doi: 10.1007/s00256-023-04292-w. Epub 2023 Feb 14.

本文引用的文献

1
Fibrosarcoma development 15 years after curettage and bone grafting of giant cell tumor of bone.骨巨细胞瘤刮除植骨术后15年发生纤维肉瘤
Orthopedics. 2014 May;37(5):e512-6. doi: 10.3928/01477447-20140430-66.
2
Effects of RANKL-Targeted Therapy in Immunity and Cancer.RANKL靶向治疗在免疫与癌症中的作用
Front Oncol. 2014 Jan 7;3:329. doi: 10.3389/fonc.2013.00329.
3
Denosumab and giant cell tumour of bone-a review and future management considerations.地舒单抗与骨巨细胞瘤——综述与未来的治疗管理思考。
Curr Oncol. 2013 Oct;20(5):e442-7. doi: 10.3747/co.20.1497.
4
Bisphosphonate therapy for unresectable symptomatic benign bone tumors: a long-term prospective study of tolerance and efficacy.不可切除的有症状良性骨肿瘤的双膦酸盐治疗:耐受性和疗效的长期前瞻性研究。
Bone. 2014 Jan;58:11-6. doi: 10.1016/j.bone.2013.10.004. Epub 2013 Oct 11.
5
Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study.地舒单抗治疗成人和骨骼成熟青少年骨巨细胞瘤的安全性和有效性:一项开放标签、平行组、2 期研究的中期分析。
Lancet Oncol. 2013 Aug;14(9):901-8. doi: 10.1016/S1470-2045(13)70277-8. Epub 2013 Jul 16.
6
Giant cell tumor of the larynx: a case of malignant sarcomatous transformation.喉巨细胞瘤:一例恶性肉瘤样转化病例
Ear Nose Throat J. 2013 Jun;92(6):E59. doi: 10.1177/014556131309200626.
7
p53 mutations may be involved in malignant transformation of giant cell tumor of bone through interaction with GPX1.p53 突变可能通过与 GPX1 相互作用而参与骨巨细胞瘤的恶性转化。
Virchows Arch. 2013 Jul;463(1):67-77. doi: 10.1007/s00428-013-1435-z. Epub 2013 Jun 8.
8
Giant cell tumor of the extremity: retrospective analysis of 621 Chinese patients from one institution.肢体巨大细胞瘤:单中心 621 例回顾性分析。
J Bone Joint Surg Am. 2012 Mar 7;94(5):461-7. doi: 10.2106/JBJS.J.01922.
9
Interferon alfa-2b for recurrent and metastatic giant cell tumor of the spine: report of two cases.干扰素 α-2b 治疗复发性和转移性脊柱巨细胞瘤:两例报告。
Spine (Phila Pa 1976). 2010 Nov 15;35(24):E1418-22. doi: 10.1097/BRS.0b013e3181e7bf5a.
10
Recurrent giant cell tumor of long bones: analysis of surgical management.长骨复发性巨细胞瘤:手术治疗分析。
Clin Orthop Relat Res. 2011 Apr;469(4):1181-7. doi: 10.1007/s11999-010-1560-9. Epub 2010 Sep 16.